Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly

Influenza Clinical Trial

Official title:

Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan´s Fragmented, Inactivated Trivalent Influenza Vaccine in Healthy Adults and Elderly

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02313740
• Other study ID #: FLU-04-IB
• Status: Completed
• Phase: N/A
• First received: December 4, 2014
• Last updated: July 20, 2015
• Start date: April 2015
• Est. completion date: June 2015

Study information

• Verified date: July 2015
• Source: Butantan Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: National Health Surveillance Agency
• Study type: Observational

Clinical Trial Summary

Prospective cohort study to evaluate safety and immunogenicity of the fragmented, inactivated trivalent Influenza vaccine produced at Butantan Institute in healthy adults and elderly. The study will include a total of 120 participants: 60 participants aged 18 to 59 years in the healthy adults group, and 60 participants aged older than 60 years in the elderly group.This study will evaluate the safety of one dose of the fragmented, inactivated trivalent Influenza vaccine in the first 3 days after vaccination, as well as its immunogenicity 21 days after vaccination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: June 2015
• Est. primary completion date: June 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy adults, male or female aged 18 to 59

• Elderly aged 60 years completed and above

• To be available to participate in the study throughout its duration (approximately 21 days)

• To have medical indication to be vaccinated against influenza

• To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.

Exclusion Criteria:

• Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control among the elderly)

• Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases

• Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements

• Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history

• Known systemic hypersensitivity to eggs or to any component of the vaccine

• History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination

• History of Guillain-Barre Syndrome or other demyelinating disease

• Diagnosis of asthma with a history of hospitalization in the last six months due to illness

• Suspected or confirmed fever in the 3 days prior to vaccination or axillary temperature greater than 37.8 ° C on the day of vaccination

• Use of corticosteroids (except topical or nasal) or other immunosuppressive drugs within 42 days before study initiation/baseline. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose =10 mg of prednisone per day for over 14 days

• Impaired coagulation due to chronic disease or due to use anticoagulant medication (warfarin or heparin) in the 7 days preceding vaccination

• Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 21 days after vaccination

• Have received influenza vaccine in the past 6 months;

• History of asplenia

• Have received blood products in the past 6 months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the first 21 days after vaccination

• have a counterindication for Influenza vaccination, including allergy to egg proteins

• Use of any investigational product within 42 days before vaccination;

• Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• Butantan Fragmented Inactivated Trivalent Influenza Vaccine
Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Butantan Institute

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccine Immunogenicity	Antibody response to each of the vaccine´s strains as measured by % seroconversion, increase in the geometric mean of hemagglutination-inhibition (HAI) titers and % seroprotection.	21 days	No
Primary	Vaccine safety assessed by unsolicited local and systemic adverse reactions up to 3 days post vaccination		3 days	Yes